These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37336258)

  • 1. Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth.
    Supron AD; Bergmark RW; Roditi RE; Buchheit KM
    Ann Allergy Asthma Immunol; 2023 Sep; 131(3):384-386. PubMed ID: 37336258
    [No Abstract]   [Full Text] [Related]  

  • 2. Decreased nasal polyp eosinophils but increased mast cells in a patient with aspirin-exacerbated respiratory disease treated with reslizumab.
    Staudacher AG; Peters AT; Carter RG; Welch KC; Stevens WW
    Ann Allergy Asthma Immunol; 2020 Oct; 125(4):490-493.e2. PubMed ID: 32629015
    [No Abstract]   [Full Text] [Related]  

  • 3. Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.
    Buchheit KM; Hacker J; Maurer R; McGill A; Ryan T; Bensko JC; Laidlaw TM
    Clin Exp Allergy; 2023 Sep; 53(9):974-977. PubMed ID: 37246613
    [No Abstract]   [Full Text] [Related]  

  • 4. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
    Bachert C; Sousa AR; Han JK; Schlosser RJ; Sowerby LJ; Hopkins C; Maspero JF; Smith SG; Kante O; Karidi-Andrioti DE; Mayer B; Chan RH; Yancey SW; Chaker AM
    J Allergy Clin Immunol; 2022 May; 149(5):1711-1721.e6. PubMed ID: 35007624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal expression of the vascular endothelial growth factor and its receptors is reduced by mepolizumab in chronic rhinosinusitis with nasal polyposis.
    Cavaliere C; Masieri S; Greco A; Lambiase A; Segatto M
    Ann Allergy Asthma Immunol; 2021 Apr; 126(4):442-443. PubMed ID: 33465456
    [No Abstract]   [Full Text] [Related]  

  • 7. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis.
    Bachert C; Zhang L; Gevaert P
    J Allergy Clin Immunol; 2015 Dec; 136(6):1431-1440. PubMed ID: 26654192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab for chronic rhinosinusitis with nasal polyps.
    Brusselle GG; Gevaert P
    Lancet Respir Med; 2021 Oct; 9(10):1081-1082. PubMed ID: 33872589
    [No Abstract]   [Full Text] [Related]  

  • 9. Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose.
    Laidlaw TM; Chu DK; Stevens WW; White AA
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1462-1467. PubMed ID: 34999274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps.
    Patel GB; Peters AT
    Ear Nose Throat J; 2021 Jan; 100(1):44-47. PubMed ID: 33035132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.
    Miss Ozuna L; Ryan T; Bensko JC; Laidlaw TM; Buchheit KM
    Ann Allergy Asthma Immunol; 2022 Apr; 128(4):469-472. PubMed ID: 35124224
    [No Abstract]   [Full Text] [Related]  

  • 12. The Effect of Aspirin on Moderate to Severe Asthmatic Patients with Aspirin Hypersensitivity, Chronic Rhinosinusitis, and Nasal Polyposis.
    Arshi S; Darougar S; Nabavi M; Bemanian MH; Fallahpour M; Shokri S; Ahmadian J; Molatefi R; Rekabi M; Moinfar Z; Hashemitari P; Eslami N
    Iran J Allergy Asthma Immunol; 2021 Jun; 20(3):287-293. PubMed ID: 34134450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.
    Patel P; Bensko JC; Bhattacharyya N; Laidlaw TM; Buchheit KM
    Ann Allergy Asthma Immunol; 2022 Mar; 128(3):326-328. PubMed ID: 34863953
    [No Abstract]   [Full Text] [Related]  

  • 14. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
    Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
    Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab Approved to Treat Chronic Rhinosinusitis with Nasal Polyposis.
    Aschenbrenner DS
    Am J Nurs; 2019 Oct; 119(10):21-22. PubMed ID: 31567245
    [No Abstract]   [Full Text] [Related]  

  • 16. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.
    Laidlaw TM; Mullol J; Fan C; Zhang D; Amin N; Khan A; Chao J; Mannent LP
    J Allergy Clin Immunol Pract; 2019; 7(7):2462-2465.e1. PubMed ID: 30954643
    [No Abstract]   [Full Text] [Related]  

  • 17. Current complications and treatment of aspirin-exacerbated respiratory disease.
    Cook KA; Stevenson DD
    Expert Rev Respir Med; 2016 Dec; 10(12):1305-1316. PubMed ID: 27817219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative management and perceived risks of sinus surgery in patients with aspirin-exacerbated respiratory disease.
    Wangberg H; Spierling Bagsic SR; Levy JM; White A
    Int Forum Allergy Rhinol; 2021 Jul; 11(7):1132-1134. PubMed ID: 33723921
    [No Abstract]   [Full Text] [Related]  

  • 19. Dysbiosis in aspirin-exacerbated respiratory disease.
    Cook KA; Domissy A; Simon RA; White AA; Modena BD
    Int Forum Allergy Rhinol; 2021 Jul; 11(7):1116-1120. PubMed ID: 33438331
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
    Buchheit KM; Sohail A; Hacker J; Maurer R; Gakpo D; Bensko JC; Taliaferro F; Ordovas-Montanes J; Laidlaw TM
    J Allergy Clin Immunol; 2022 Aug; 150(2):415-424. PubMed ID: 35460728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.